14-Oct-2026    Nucleic acid sensors video with Dr Olivier Laczka  
 
9-Oct-2026    StockWire X: Why Your Immune System Doesn’t Attack You, and What Noxopharm Is Testing  
 
4-Sep-2026    Investor Presentation September 2026  
 
28-Aug-2026    The Stock Network interview with Dr Olivier Laczka  
 
21-Aug-2026    CEO Letter – Reflections on global mRNA cancer vaccine news  
 
11-Aug-2026    CEO Dr Olivier Laczka discusses Nature Immunology paper  
 
26-Jul-2026    ASX Briefs interview with Dr Olivier Laczka  
 
16-Jul-2026    Hudson Institute partnership video with Dr Olivier Laczka  
 
12-Jun-2026    CEO Dr Olivier Laczka interview with Proactive Investors  
 
22-May-2026    Sofra technology draws global interest as CSL to present vaccine delivery data  
 
22-Apr-2026    Noxopharm flags prolonged skin retention data for SOF-SKN as it moves toward human trial  
 
21-Apr-2026    Noxopharm appoints Dr Olivier Laczka as Chief Executive Officer | BioMelbourne Network  
 
13-Feb-2026    Noxopharm says paper reveals science behind its immune system platform  
 
10-Feb-2026    Tiny one- to three-base RNAs could help stop autoimmune inflammation, study suggests  
 
10-Feb-2026    Tiny RNA fragments unlock massive autoimmune treatment potential - Hudson Institute of Medical Research  
 
18-Nov-2025    Noxopharm 2025 AGM Corporate Presentation  
 
29-Oct-2025    World-first RNA trial a breakthrough for lupus patients  
 
17-Sep-2025    Stockhead interview - Noxopharm has the ‘burning fire’ of inflammation squarely in its sights  
 
28-Aug-2025    Sofra technology platform presentation  
 
29-May-2025    Ausbiz interview - The small cap tackling inflammatory disease  
 
19-Nov-2024    Noxopharm 2024 AGM Corporate Presentation  
 
3-Sep-2024    Ausbiz interview on brain cancer research  
 
20-Aug-2024    Proactive Investors interview: First trial for SOF-SKN™  
 
19-Aug-2024    Ausbiz interview on HERACLES trial  
 
14-Jun-2024    Chief Executive Officer Letter  
 
16-Nov-2023    Noxopharm 2023 AGM Corporate Presentation  
 
16-Oct-2023    Noxopharm talks partnership with Hudson Institute of Medical Research  
 
22-May-2023    Noxopharm hails new Sofra™ drug inflammation results  
 
17-Nov-2022    Noxopharm 2022 AGM Corporate Presentation  
 
4-Oct-2022    Ausbiz interview regarding pancreatic cancer research  
 
14-Sep-2022    Noxopharm reveals encouraging new pancreatic cancer preclinical study data  
 
7-Jun-2022    Noxopharm New Corporate Presentation June 2022